Evidence map›Paper›PMID 40390221›Full record

ArticleCNS & neurological disorders drug targets2025

Trends in Research on Gantenerumab for Alzheimer's Disease: A Bibliometric and Thematic Analysis.

Siddig Ibrahim Abdelwahab, Manal Mohamed Elhassan Taha, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ieman A Aljahdali, Omar Oraibi, Sohaila Ali, Bassem Oraibi, Abdullah Farasani, Ahmed Ali Jerah and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in CNS & neurological disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Siddig Ibrahim AbdelwahabHealth Research Centre, Jazan University, Jazan, Saudi Arabia.
Manal Mohamed Elhassan TahaSubstance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
Hassan Ahmad AlfaifiPharmaceutical Care Administration (Jeddah Second Health Cluster), Ministry of Health, Jeddah, Saudi Arabia.
Amal Hamdan AlzahraniDepartment of Pharmacology and Toxicology, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Ieman A AljahdaliDepartment of Clinical Laboratory Sciences, Taif University, Taif, Saudi Arabia.
Omar OraibiDepartment of Internal Medicine, College of Medicine, Jazan University, Jazan, Saudi Arabia.
Sohaila AliDepartment of Family and Community Medicine, College of Medicine, Jazan University, Jazan, Saudi Arabia.
Bassem OraibiHealth Research Center, Jazan University, Jazan, Saudi Arabia.
Abdullah FarasaniDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
Ahmed Ali JerahDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
Yasir Osman Hassan BabikerAnaesthesia & Intensive Care, Department of Surgery, College of Medicine, Jazan University, Jazan, Saudi Arabia.
Anas A AhmedFamily and Community Medicine Department, College of Medicine, Jazan University, Jazan, Saudi Arabia.
Gassem GohalDepartment of Pediatric Medicine, Faculty of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Osama AlbasheerDepartment of Family and Community Medicine, College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.

Funding

Deanship of Graduate Studies and Scientific Research, Jazan University, Saudi Arabia RG24-M014
6 · The paper itself

Abstract

introductionGantenerumab (GR), a promising therapeutic agent for Alzheimer's disease (AD), has been the subject of extensive research. In this study, we aimed to provide a comprehensive analysis of the literature on GR.

methodsA systematic search was conducted using the PubMed, Scopus, and Web of Science databases. VOSviewer and Bibliometrix were utilized to analyze bibliographic data.

resultsThe analysis of the literature on GR revealed distinct publication trends. Reviews accounted for 52% of the records, followed by research articles (31%). The United States contributed the highest proportion of publications (26%).

conclusionGR-related literature showed sustained thematic focus, growing international collaboration, and a steady rise in publication volume within the field of AD. These findings highlight the continued need for clinical and biomarker-focused investigations to advance therapeutic development in AD.

Indexed as

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedBibliometricsBiomedical ResearchAmyloid beta-PeptidesHumansAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedgantenerumabAlzheimer's diseaseamyloid-betabibliometric analysisbiomarkers.clinical trialscognitive declineGantenerumab

Identifiers

PMID40390221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.